Understanding the FDA Warning on Reglan and Tardive Dyskinesia in Washington

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one has taken Reglan and developed uncontrollable muscle movements, you may be facing tardive dyskinesia. The FDA has issued a black box warning about this risk with long-term use. This page explains the warning, what it means in practice, and how to recognize early signs.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its association with tardive dyskinesia (TD) is a serious concern that has led to a boxed warning from the U.S. Food and Drug Administration. For patients in Washington who have developed TD after using Reglan, understanding the medical and legal landscape is critical, particularly regarding the statute of limitations for filing a claim. Tardive dyskinesia is a movement disorder characterized by potentially irreversible, involuntary movements of the face, tongue, trunk, or extremities. The clinical presentation often includes repetitive, purposeless motions such as lip smacking, grimacing, or rapid eye blinking. Diagnosis is based on a history of exposure to a dopamine-blocking agent like metoclopramide and the presence of characteristic movements after ruling out other causes. The condition can be disfiguring and may persist even after the offending drug is discontinued. Reglan’s active ingredient, metoclopramide, is a dopamine receptor antagonist that increases gastrointestinal motility. Its pharmacology involves blocking dopamine D2 receptors in the chemoreceptor trigger zone, which reduces nausea and vomiting. However, this same mechanism can lead to adverse effects in the central nervous system. Chronic blockade of dopamine receptors in the basal ganglia is believed to cause upregulation of dopamine receptors, leading to the involuntary movements seen in TD. The risk of developing TD increases with longer duration of treatment and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA has mandated a boxed warning stating that metoclopramide can cause TD, which may be irreversible, and that the risk grows with treatment duration and total dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the maximum recommended treatment duration is 12 weeks, and for gastroesophageal reflux, it is also 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these limits, many patients have been prescribed Reglan for extended periods, increasing their risk.

Mechanistic Pathways and Risk Factors

The mechanistic pathway linking Reglan to TD involves prolonged dopamine receptor blockade. Metoclopramide crosses the blood-brain barrier and binds to D2 receptors in the striatum. Over time, this blockade leads to compensatory changes, including receptor supersensitivity. When the drug is reduced or stopped, the heightened sensitivity can result in uncontrolled movements. The FDA warns that metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates the timeline between exposure and documented harm, as symptoms may not become apparent until after the drug is discontinued. From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning clearly states that Reglan is contraindicated in patients with a history of TD and that it should be used for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients and healthcare providers may not have been fully aware of these risks, especially before the warning was strengthened. The FDA also advises that Reglan tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these precautions, off-label or prolonged use has occurred, leading to harm.

Legal Considerations and Statute of Limitations in Washington

For affected patients in Washington, attorney-related considerations are important. The statute of limitations for personal injury claims, including those related to medication-induced TD, generally requires filing within a certain period after the injury is discovered or should have been discovered. In Washington, the statute of limitations for product liability and personal injury claims is typically three years from the date of injury or discovery. However, the timeline between exposure and documented harm can be complex. TD may develop months or years after starting Reglan, and symptoms may be subtle initially. The FDA notes that metoclopramide can mask TD signs, which may delay diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, the clock for the statute of limitations may start when the patient first recognized the connection between their symptoms and Reglan use, or when a physician diagnosed TD. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their case. Key factors include the duration of Reglan use, the presence of adequate warnings, and the timing of diagnosis. The FDA’s boxed warning emphasizes that Reglan should be discontinued immediately if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to do so may strengthen a claim of inadequate monitoring or warning. In summary, Reglan’s link to TD is well-established through its pharmacology and clinical evidence. The risk is dose- and duration-dependent, and the FDA has mandated strong warnings. For Washington patients, the statute of limitations requires prompt action after discovery of harm. Legal counsel can help navigate the timeline and evidence needed to pursue a claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Washington?

In Washington, the statute of limitations for personal injury and product liability claims is generally three years from the date the injury was discovered or should have been discovered. For tardive dyskinesia caused by Reglan, the clock may start when the patient first recognized the connection between their symptoms and Reglan use, or when a physician diagnosed TD. It is crucial to consult an attorney promptly to ensure your claim is filed within the applicable time frame.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) is a dopamine receptor antagonist. Prolonged blockade of dopamine D2 receptors in the brain can lead to receptor supersensitivity, resulting in involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Metoclopramide

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.